Key Drivers
- Strong liquidity
- Healthy margins
- Elevated leverage
AIAI Summary
NUTX should be treated as an event‑driven cash‑conversion play: attractive margins and low multiples hinge on collecting ~$325–387M of arbitration‑related receivables and resolving ongoing legal/disclosure issues, so investors must prioritize independent verification of receivable collectability and monitor arbitration/legal outcomes before relying on reported FCF or valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Healthy margins
- •Elevated leverage
NUTX generates strong cash and attractive margins with modest valuation but is offset by elevated leverage, large receivables, and complex consolidated earnings that cloud quality.
Price Behavior
Key Price Behavior Insights:
- •Sustained downtrend
- •Repeated support tests
- •Elevated volatility
Over the last month NUTX has trended down from early‑March highs to a March 20 low, repeatedly testing $85–90 support while stalling at $105–112 resistance, with rapid declines implying elevated short-term volatility and continued downside risk absent a close above $105.
Rapid, large decline from early
Sentiment & News
Key News Insights:
- •Strong revenue growth
- •Receivables overhang
- •Investor investigations
Nutex Health posted sharply improved 2025 results and buyback plans but faces a $387M receivables overhang, a $55M arbitration true-up, March 2026 investor probes and disclosure/legal risk that cloud the stock despite upside catalysts.
Positive operating momentum is offset by near-term cash and legal/disclosure risk, likely keeping valuation under pressure until receivables clarity and legal outcomes are resolved
Similar Companies in Healthcare
Other companies in the same sector with AI ratings